Digitalis: A dangerous drug in atrial fibrillation?

Heart

Volumn 94, Issue 12, 2008, Pages 1654-

  Testa, L ^a   Bhindi, R ^a   Banning, A P ^a  

^a JOHN RADCLIFFE HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIARRHYTHMIC AGENT; ANTICOAGULANT AGENT; DIGITALIS; WARFARIN; XIMELAGATRAN;

DRUG WITHDRAWAL; HEART ATRIUM FIBRILLATION; HEART FAILURE; HUMAN; LETTER; LIVER TOXICITY; MORTALITY; PRIORITY JOURNAL; PROPHYLAXIS; STROKE;

ANTICOAGULANTS; ATRIAL FIBRILLATION; AZETIDINES; BENZYLAMINES; DIGITALIS; DIGOXIN; DRUG COMBINATIONS; HEMORRHAGE; HUMANS; PHYTOTHERAPY;

EID: 56749174073     PISSN: 13556037     EISSN: 1468201X     Source Type: Journal    
DOI: None     Document Type: Letter

References (9)

1. Gjesdal K, Feyzi J, Olsson SB. Digitalis: a dangerous drug in atrial fibrillation? An analysis of the SPORTIF III and V data. Heart 2008;94;191-6.
2. Testa L, Biondi-Zoccai GG, Dello Russo A, et al. Rate-control vs. rhythm-control in patients with atrial fibrillation: a meta-analysis. Eur Heart J 2005;26:2000-6.
3. Testa L, Andreotti F, Trotta G, et al. Ximelagatran/ melagatran versus conventional anticoagulant therapy: meta-analysis of 13 randomised controlled trials enrolling 22639 patients. European Society of Cardiology/World Congress of Cardiology 2007. Oral Presentation for the Young Investigator Award in Thrombosis. Int J Cardiol 2007;122:117-24.
4. Testa L, Bhindi R, Agostoni P, et al. The direct thrombin inhibitor ximelagatran/melagatran: a systematic review on clinical applications and an evidence based assessment of risk benefit profile. Expert Opin Drug Saf 2007;6:397-406.
5. Testa L, Van Gaal W, Agostoni P, et al. Ximelagatran versus warfarin in the prevention of atrial fibrillation-related stroke: both sides of the story. Stroke 2007;38:e57.
6. Anonymous. AstraZeneca receives action letter from FDA for Exanta™ (ximelagatran). Available at http://www.medscape.com/pages/ editorial/pressreleases/pr-cm-astrazeneca9 (accessed 15 September 2008).
7. Anonymous. Successful outcome of the mutual recognition procedure for Exanta™ (ximelagatran) in Europe. Press release from European Agency for the Evaluation of Medicinal Products (EMEA). Available at http://www.astrazeneca.com/pressrelease/1898.aspx (accessed 15 September 2008).
8. AstraZeneca decides to withdraw Exanta™ (ximelagatran). Press release from AstraZeneca international, February 14, 2006. Available at http://www.astrazeneca.com/pressrelease/5217.aspx (accessed 15 September 2008).
9. Gheorghiade M, Adams KF Jr, Colucci WS. Digoxin in the management of cardiovascular disorders. Circulation 2004;109:2959-64.